| Title |
Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma
|
|---|---|
| Published in |
Advances in Therapy, November 2013
|
| DOI | 10.1007/s12325-013-0062-z |
| Pubmed ID | |
| Authors |
William Dunlop, Louise Heron, Georgia Fox, Maire Greaney |
| Abstract |
The economic burden of asthma on the UK National Health Service (NHS) is the largest among allergic diseases. Current asthma guidelines recommend adding a long acting β2-agonist (LABA) to a low-dose inhaled corticosteroid (ICS) in patients who are on ICS monotherapy and have uncontrolled asthma. The fixed-dose combination of fluticasone propionate and salmeterol xinafoate (FP/SAL), available in a pressurized metered-dose inhaler (pMDI) device, is the most commonly prescribed ICS/LABA combination. An additional fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in pMDI is now available. In a 12-week non-inferiority study, FP/FORM demonstrated comparable efficacy to FP/SAL. The present analysis estimates the annual budget impact for the UK NHS using FP/FORM as an alternative to FP/SAL. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 39 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 20% |
| Student > Ph. D. Student | 6 | 15% |
| Student > Postgraduate | 5 | 13% |
| Student > Master | 5 | 13% |
| Student > Doctoral Student | 3 | 8% |
| Other | 4 | 10% |
| Unknown | 9 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Nursing and Health Professions | 4 | 10% |
| Agricultural and Biological Sciences | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 12 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2014.
All research outputs
#15,304,580
of 22,761,738 outputs
Outputs from Advances in Therapy
#1,290
of 2,337 outputs
Outputs of similar age
#132,524
of 215,720 outputs
Outputs of similar age from Advances in Therapy
#8
of 15 outputs
Altmetric has tracked 22,761,738 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,337 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,720 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.